HIV
Conditions
Keywords
Acceptability and Adherence to methods
Brief summary
The IUD is an extremely effective method of contraception yet few women use it worldwide. Considered safe to use in HIV+ women, few studies have evaluated its use among those using antiretroviral therapy. The only prior randomized trial looking at the IUD compared to hormonal contraception noted a high rate of IUD discontinuations. Understanding IUD acceptability and continuation is critical to improve utilization. * Objective 1: Determine WHO medical eligibility and the willingness for IUD placement * Objective 2: Compare method-related side effects and adverse events * Objective 3: Assess the 1-year acceptability and continuation rates Methods: To address our objectives the investigators have designed a two Phase Study: * A cross-sectional screening to evaluate contraceptive medical eligibility and desirability * A randomized controlled trial that will compare acceptability and adherence to DMPA compared to the Copper IUD: enrolling 200 women stable on antiretroviral therapy to follow for 1 year
Interventions
DRUGCopper IUD
Copper IUD (CuT360)
DMPA 150 mg IM q 3 months
Sponsors
University of North Carolina
National Institute of Allergy and Infectious Diseases (NIAID)
Emory University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Can provide informed consent * Women ages 18-45 * Known HIV + status on antiretroviral therapy for at least 6 months * Not currently pregnant * Willing to initiate either DMPA or CuT380A-IUD. Women currently using DMPA or CuT380A-IUD will be excluded * Do not desire to become pregnant within next 12 months * Intend to stay in Lilongwe region for the duration of the study * No known uterine anomalies based upon history * Greater than or equal to 4 weeks post partum * No known or suspected genital tract cancer * No evidence of current pelvic inflammatory disease or cervicitis. Women with cervicitis at the time of examination will be treated with antibiotics and eligibility will be reassessed at a follow-up visit at least 7 days after treatment * No pelvic inflammatory disease within prior 3 months * No contraindications to DMPA or the CuT380A-IUD per the WHO medical eligibility criteria or Malawi National Reproductive Health Service Delivery Guidelines, 2007 * Based on clinical assessment, no condition that would preclude start of study intervention
Exclusion criteria
* Women ages younger than18 or older than 45 * Known HIV + status on antiretroviral therapy less than 6 months or not on antiretroviral therapy * Pregnant * Uterine anomaly * Less than 4 weeks post partum * Suspected genital tract cancer Inclusion Criteria: •Current STI or PID
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adherence | 1 year | Number of clients continuing with method at 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 1 year | -Number of clients who experience adverse events such as pelvic inflammatory disease, lower genital tract infection, and infection related complications, such as abdominal pain, and irregular vaginal bleeding, as well as lower tract infection determined by clinical examination. Side effects such as abnormal vaginal discharge, abnormal bleeding, IUCD expulsion, and other side effects, as measured by clinical examination and client self-report. -Risk of excessive vaginal bleeding or anemia: determined by self report and hemoglobin level |
Countries
Malawi
Outcome results
None listed